On February 8, 2024, Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, announced the completion of a $120 million financing co-led by Viking Global Investors and Cormorant Asset Management with participation from The Column Group, LYFE Capital, Schroders Capital, Willett Advisors, Ysios Capital Partners, Euclidean Capital, SymBiosis, Alexandria Venture Investments, Berkeley Frontier Fund, Sphera Biotech Master Fund LP, Spur Capital Partners, UCB Ventures, and UC Investments. Wilson Sonsini Goodrich & Rosati advised Neurona Therapeutics on the transaction.

Proceeds from the financing will be used to advance the company’s pipeline of cell therapies for multiple indications, including its lead investigational candidate, NRTX-1001. NRTX-1001 is being evaluated in an ongoing open-label, single-arm Phase I/II clinical trial for treatment of drug-resistant mesial temporal lobe epilepsy and has potential application in Alzheimer’s disease and other disorders of the nervous system.

The Wilson Sonsini team that advised Neurona Therapeutics on the transaction included Ken Clark, Lance Brady, Andrew Collins, Jacie Valentine, and Jacob Morales.

For more information, please see Neurona Therapeutics' press release.